Flow Antigen Test News Today : Breaking News, Live Updates & Top Stories | Vimarsana

It won't help protect you on the plane. there are other ways to encourage people to be vaccinated. i think you're seeing that right now. >> you were the testing czar. i know you have seen this announcement, you have been sort of studying it by the white house that they are purchasing an additional $1 billion in rapid tests. what's the significant of that? >> it's very significant. we worked as hard as we could to develop rapid testing. the first was the card test of that lateral flow antigen test. we bought the entire u.s. production for many, many months. so these rapid tests are very good. t...

Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer ® biologics and pre|CISION™ tumour targeted chemotherapies.   The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the reliance ...